menu search

DSNKY / Daiichi Sankyo Company, Limited (DSKYF) Q1 2022 Results - Earnings Call Transcript

Daiichi Sankyo Company, Limited (DSKYF) Q1 2022 Results - Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2022 Earnings Conference Call July 29, 2022 2:00 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Wataru Takasaki - Executive Officer, Head, R&D Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Fumiyoshi Sakai - Crédit Suisse Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Kazuaki Hashiguchi - Daiwa Securities Hiroyuki Okuzawa Okuzawa speaking. Thank you very much for joining Daiichi Sankyo's Financial Results Presentation out of your very busy schedule today. Read More
Posted: Aug 1 2022, 17:08
Author Name: Seeking Alpha
Views: 092054

DSNKY News  

Trending Tickers: AT&T, Merck-Daiichi Sankyo, Klaviyo: Trending tickers October 29, 2023

By Yahoo Finance
October 20, 2023

Trending Tickers: AT&T, Merck-Daiichi Sankyo, Klaviyo: Trending tickers October 29, 2023

Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japan more_horizontal

Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck

By Market Watch
October 19, 2023

Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck

Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly d more_horizontal

Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates

By Reuters
October 19, 2023

Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates

Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) candid more_horizontal

Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Call Transcript

By Seeking Alpha
July 31, 2023

Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Call Transcript

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2023 Earnings Conference Call July 31, 2023 2:00 AM ET Company Participants Kentaro Asakura - Vice Pr more_horizontal

Japan's Daiichi Sankyo gets approval for COVID vaccine, first for country

By Reuters
July 31, 2023

Japan's Daiichi Sankyo gets approval for COVID vaccine, first for country

A Japanese health ministry panel recommended approval for Daiichi Sankyo's mRNA-based COVID-19 vaccine in what would be the nation's first home-grown more_horizontal

Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment

By Reuters
July 20, 2023

Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment

The U.S. Food and Drug Administration (FDA) approved Japan-based Daiichi Sankyo Co's treatment for newly diagnosed patients with an aggressive type of more_horizontal

Daiichi Sankyo: There Is A Lot Of Room To Grow

By Seeking Alpha
May 26, 2023

Daiichi Sankyo: There Is A Lot Of Room To Grow

Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in cancer after more than a decade of more_horizontal

Japan's Daiichi Sankyo invests $80 million to expand Brazilian plant

By Reuters
May 22, 2023

Japan's Daiichi Sankyo invests $80 million to expand Brazilian plant

Japanese drugmaker Daiichi Sankyo said on Monday it will invest around 400 million reais ($80 million) to expand its Brazilian operations, part of a p more_horizontal


Search within

Pages Search Results: